CL2020003116A1 - Derivado de anillo heteroaromático bicíclico - Google Patents

Derivado de anillo heteroaromático bicíclico

Info

Publication number
CL2020003116A1
CL2020003116A1 CL2020003116A CL2020003116A CL2020003116A1 CL 2020003116 A1 CL2020003116 A1 CL 2020003116A1 CL 2020003116 A CL2020003116 A CL 2020003116A CL 2020003116 A CL2020003116 A CL 2020003116A CL 2020003116 A1 CL2020003116 A1 CL 2020003116A1
Authority
CL
Chile
Prior art keywords
heteroaromatic ring
bicyclic heteroaromatic
ring derivative
compounds
hydrates
Prior art date
Application number
CL2020003116A
Other languages
English (en)
Spanish (es)
Inventor
Masahiko Kinebuchi
Takekazu Kondou
Koji Ochiai
Yosuke NISHIGAYA
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of CL2020003116A1 publication Critical patent/CL2020003116A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2020003116A 2018-08-21 2020-11-30 Derivado de anillo heteroaromático bicíclico CL2020003116A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018154411 2018-08-21

Publications (1)

Publication Number Publication Date
CL2020003116A1 true CL2020003116A1 (es) 2021-04-16

Family

ID=69593150

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003116A CL2020003116A1 (es) 2018-08-21 2020-11-30 Derivado de anillo heteroaromático bicíclico

Country Status (19)

Country Link
US (1) US11952387B2 (https=)
EP (1) EP3842439A4 (https=)
JP (1) JP7309725B2 (https=)
KR (1) KR20210046649A (https=)
CN (2) CN112752761B (https=)
AU (1) AU2019324089B2 (https=)
BR (1) BR112021002515A2 (https=)
CA (1) CA3104054A1 (https=)
CL (1) CL2020003116A1 (https=)
CO (1) CO2021000512A2 (https=)
IL (1) IL278885A (https=)
MX (1) MX2020013039A (https=)
MY (1) MY200452A (https=)
PH (1) PH12020551991A1 (https=)
SA (1) SA520420914B1 (https=)
SG (1) SG11202012616RA (https=)
TW (1) TWI811428B (https=)
WO (1) WO2020040104A1 (https=)
ZA (1) ZA202101146B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024231436A1 (en) * 2023-05-11 2024-11-14 Arxada Ag Hydrogenation of cyclic ketones

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT65486B (en) 1975-08-28 1978-03-24 Lilly Co Eli Process for the preparation of carbonil-substituted 1-sulfonylbenzimidazoles
JPH0649066B2 (ja) * 1985-02-14 1994-06-29 積水化学工業株式会社 医療用粘着シ−トもしくはテ−プ
FR2687574B1 (fr) * 1992-02-25 1995-05-05 Rhone Poulenc Rorer Sa Nouvelle application therapeutique de derives du pyridylpyrrolothiazole carboxamide.
US5349068A (en) 1992-04-15 1994-09-20 Sterling Winthrop Inc. 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents
JPH07188017A (ja) * 1993-09-30 1995-07-25 Souyaku Gijutsu Kenkyusho:Kk チアジアゾール誘導体を含有する抗ウイルス剤
US5453433A (en) 1994-05-13 1995-09-26 Sterling Winthrop Inc. Thiadiazoles and antipicornaviral compositions
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
JPH11106340A (ja) 1997-10-02 1999-04-20 Sumitomo Pharmaceut Co Ltd Stat6活性化阻害剤
US6258831B1 (en) * 1999-03-31 2001-07-10 The Procter & Gamble Company Viral treatment
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0321003D0 (en) * 2003-09-09 2003-10-08 Angeletti P Ist Richerche Bio Compounds, compositions and uses
US7229480B2 (en) 2004-02-13 2007-06-12 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
EP2016075A1 (en) 2006-05-03 2009-01-21 AstraZeneca AB Thiazole derivatives and their use as anti-tumour agents
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
HRP20151128T1 (hr) * 2007-09-27 2015-11-20 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Imidazolotiadiazoli za uporabu kao inhibitori protein kinaze
EP2307425B1 (en) * 2008-07-29 2014-03-26 Merck Patent GmbH Imidazothiadiazoles derivatives
CA2735875A1 (en) * 2008-09-03 2010-03-11 Boehringer Ingelheim International Gmbh Use of quinazoline derivatives for the treatment of viral diseases
ES2665277T3 (es) 2009-03-13 2018-04-25 Katholieke Universiteit Leuven K.U. Leuven R&D Análogos de purina y su uso como agentes inmunosupresores
US8815918B2 (en) 2009-04-02 2014-08-26 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
GB201115665D0 (en) 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy
US9309236B2 (en) 2011-10-05 2016-04-12 The Board Of Trustees Of The Leland Stanford Junior University PI-kinase inhibitors with broad spectrum anti-infective activity
EP3409666A3 (en) 2012-06-07 2019-01-02 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
WO2014078813A1 (en) 2012-11-19 2014-05-22 Irm Llc Compounds and compositions for the treatment of parasitic diseases
SG11201504291SA (en) 2012-12-20 2015-07-30 Ucb Biopharma Sprl Therapeutically active pyrazolo-pyrimidine derivatives
EP3004060B1 (en) 2013-05-30 2019-11-27 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
RU2689788C2 (ru) 2014-01-22 2019-05-29 Куровир Аб ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ СОЕДИНЕНИЙ
JP6678599B2 (ja) 2014-06-13 2020-04-08 ユニバーシティー オブ ロチェスター 小分子排出ポンプ阻害剤
GB201410816D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201410815D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201410817D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D Therapeutic agents
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
CN107949563B (zh) 2015-06-24 2020-06-05 库洛维公司 治疗中有用的吡唑并[1,5-a]三嗪-4-胺衍生物
EP3118198A1 (en) 2015-07-13 2017-01-18 MMV Medicines for Malaria Venture Anti-malarial agents
WO2017044889A1 (en) 2015-09-10 2017-03-16 The Regents Of The University Of California Lrh-1 modulators
WO2017053192A1 (en) 2015-09-21 2017-03-30 The Board Of Regents Of The University Of Texas System Biomarkers of response to hif-2-alpha inhibition in cancer and methods for the use thereof
GB201517263D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201517264D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201521767D0 (en) 2015-12-10 2016-01-27 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D Therapeutic agents
WO2017147526A1 (en) 2016-02-26 2017-08-31 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
US20190358196A1 (en) 2016-07-27 2019-11-28 Henry C. Lowe Pi 4-kinase inhibitor as a therapeutic for viral hepatitis, cancer, malaria. autoimmune disorders and inflammation, and a radiosensitizer and immunosuppressant

Also Published As

Publication number Publication date
WO2020040104A1 (ja) 2020-02-27
TWI811428B (zh) 2023-08-11
JPWO2020040104A1 (ja) 2021-08-12
EP3842439A4 (en) 2022-04-27
CN118084937A (zh) 2024-05-28
ZA202101146B (en) 2022-07-27
AU2019324089B2 (en) 2024-06-13
BR112021002515A2 (pt) 2021-07-27
KR20210046649A (ko) 2021-04-28
US20220332730A1 (en) 2022-10-20
AU2019324089A1 (en) 2020-12-10
SG11202012616RA (en) 2021-02-25
US11952387B2 (en) 2024-04-09
CN112752761A (zh) 2021-05-04
CO2021000512A2 (es) 2021-01-29
JP7309725B2 (ja) 2023-07-18
MY200452A (en) 2023-12-27
CN112752761B (zh) 2024-03-29
IL278885A (en) 2021-01-31
CA3104054A1 (en) 2020-02-27
MX2020013039A (es) 2021-02-26
SA520420914B1 (ar) 2023-12-25
TW202021971A (zh) 2020-06-16
PH12020551991A1 (en) 2021-08-02
EP3842439A1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
NI202000092A (es) Compuestos
CO2021008681A2 (es) Inhibidor de 15-pgdh
CY1122296T1 (el) Θεραπευτικες ενωσεις χρησιμες για την προφυλακτικη ή θεραπευτικη αγωγη μολυνσης ιου ηiv
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
UY35362A (es) Compuestos terapéuticos
UY35263A (es) Compuestos terapéuticos
MA40302B1 (fr) Dérivés de carbazole
CL2020000487A1 (es) Agentes antivirales contra la hepatitis b.
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
BR112017006253A2 (pt) novos compostos
CU20200051A7 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
EA201792021A1 (ru) Ингибитор jak
MX391647B (es) Derivados heterociclicos de seis miembros y composicion farmaceutica que los comprende.
CL2017002745A1 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
PH12019501178A1 (en) Thiopene derivatives as antiviral agents
CO2018004573A2 (es) Derivados de fenilo como agonistas del receptor 2 de cannabinoides
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
MX2018013133A (es) Compuesto de pirazolo[1,5-a]pirimidina.
CL2020000376A1 (es) Compuesto pentacíclico.
CL2018001067A1 (es) Compuesto piranodipiridínico.
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
EA201990238A1 (ru) ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
CL2020003116A1 (es) Derivado de anillo heteroaromático bicíclico